The free‐to‐total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer
Open Access
- 1 June 1999
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 83 (9) , 1003-1006
- https://doi.org/10.1046/j.1464-410x.1999.00085.x
Abstract
Objectives To analyse the role of the ratio of serum free (f) to total (t) prostatic specific antigen (f/tPSA) as a predictor of the pathological features in patients with clinical stage T1c disease submitted for radical prostatectomy. Patients and methods Total and fPSA were determined before surgery in 76 consecutive patients with clinical stage T1cN0M0 disease and a serum tPSA level of 4–20 ng/mL. The pathological stage was defined as organ‐confined in 47 (62%), with capsular penetration in 27 (35%) and seminal vesicle infiltration in two (3%). In 18 of the specimens (24%) the surgical margins were positive. The pathology was favourable in 41 patients (55%). Total and fPSA were determined using the Tandem and Tandem‐free PSA immunoassays (Hybritech Inc, Belgium) Results The mean tPSA was: 8.7 ng/mL when the tumour was organ‐confined and 8.6 ng/mL when the disease was extraprostatic (P>0.05); 8.4 ng/mL when the tumour was specimen‐confined and 9.3 ng/mL when positive margins or seminal vesicle involvement were detected (P>0.05); and 8.3 ng/mL when the pathology was favourable and 9.0 ng/mL when unfavourable (P>0.05). The f/tPSA was 11.8% when the tumour was organ‐confined and 9.1% when it was not (PPP<0.008). A threshold of 11% f/tPSA provided an odds ratio for organ‐confined disease of 2.7, for specimen‐confined disease of 7.6 and for a favourable pathology of 3.9. Conclusion The f/tPSA seems to provide useful information in the prediction of the pathological features of patients with clinical T1c prostate cancer and a tPSA of 4.1–20 ng/mL.Keywords
This publication has 15 references indexed in Scilit:
- THE USE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN FOR STAGING CLINICALLY LOCALIZED PROSTATE CANCERJournal of Urology, 1998
- INTERPRETATION OF FREE PROSTATE SPECIFIC ANTIGEN CLINICAL RESEARCH STUDIES FOR THE DETECTION OF PROSTATE CANCERJournal of Urology, 1998
- Comparison of Percent Free Prostate Specific Antigen and Prostate Specific Antigen Density as Methods to Enhance Prostate Specific Antigen Specificity in Early Prostate Cancer Detection in Men With Normal Rectal Examination and Prostate Specific Antigen Between 4.1 and 10 ng./ml.Journal of Urology, 1997
- Combination of Prostate-Specific Antigen, Clinical Stage, and Gleason Score to Predict Pathological Stage of Localized Prostate CancerJAMA, 1997
- The Free-to-Total Serum Prostate Specific Antigen Ratio for Staging Prostate CarcinomaJournal of Urology, 1997
- The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancerUrology, 1996
- Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total psa, prostate volume, and ageUrology, 1996
- Free-to-Total Prostate Specific Antigen Ratio as a Single Test for Detection of Significant Stage T1c Prostate CancerJournal of Urology, 1996
- Free, complexed and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostateUrology, 1996
- Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsinClinical Chemistry, 1991